Trials / Conditions / Recurrent Head and Neck Cancer

Recurrent Head and Neck Cancer

23 registered clinical trials studyying Recurrent Head and Neck Cancer — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer NCT07501650	Thomas Jefferson University	Phase 1
Active Not Recruiting	Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinom NCT06790966	PDS Biotechnology Corp.	Phase 3
Recruiting	Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treat NCT06869473	Gruppo Oncologico del Nord-Ovest	Phase 2
Recruiting	PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC NCT06239220	Glenn J. Hanna	Phase 2
Recruiting	Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irra NCT05738187	University Hospital, Strasbourg, France	N/A
Active Not Recruiting	Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carci NCT05980000	Washington University School of Medicine	Phase 2
Terminated	BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) NCT04969861	Nektar Therapeutics	Phase 2 / Phase 3
Completed	A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Nec NCT04902027	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1
Completed	Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC NCT04260126	PDS Biotechnology Corp.	Phase 2
Recruiting	A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With NCT04534205	BioNTech SE	Phase 2 / Phase 3
Completed	Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract NCT04673929	Royal Marsden NHS Foundation Trust	—
Terminated	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer NCT03937141	Chinook Therapeutics, Inc. (formerly Aduro)	Phase 2
Completed	Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/N NCT03754933	GeoVax, Inc.	Phase 1 / Phase 2
Terminated	Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Live NCT02842125	MultiVir, Inc.	Phase 1 / Phase 2
Active Not Recruiting	Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell NCT03691714	Trisha Wise-Draper	Phase 2
Completed	Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of t NCT02289209	Dan Zandberg	Phase 2
Unknown	Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer NCT02567383	Shin Kong Wu Ho-Su Memorial Hospital	Phase 2
Completed	Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer NCT02422979	Rakuten Medical, Inc.	Phase 1 / Phase 2
Completed	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of NCT02358031	Merck Sharp & Dohme LLC	Phase 3
Completed	A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Nec NCT01620242	UNICANCER	Phase 2
Terminated	A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck C NCT01606566	PCI Biotech AS	Phase 2
Completed	Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer NCT01255800	University of Colorado, Denver	Phase 1
Terminated	Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer NCT00088907	National Cancer Institute (NCI)	Phase 3